Table 2.
Factors associated with treatment adherence in univariate and multivariate analyses, Hopa State Hospital, 2015–2016 (n=395 )
| Univariate analysis | Multivariate analysis (Backward: LR) | |||||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |||
| Age group (years) | ||||||||
| 15–44 | 1 | |||||||
| 45–64 | 1.365 | 0.647–2.881 | 0.414 | – | – | NS | ||
| ≥65 | 1.437 | 0.670–3.082 | 0.351 | |||||
| Gender (woman compared to man) | 1.251 | 0.798–1.961 | 0.328 | – | – | NS | ||
| Education level (per 1 level increase) | 1.070 | 0.891–1.285 | 0.470 | – | – | |||
| Occupation (working actively compared | 0.951 | 0.618–1.465 | 0.821 | – | – | NS | ||
| to not working) | ||||||||
| Fagerström test score (per 1 score | 0.929 | 0.832–1.038 | 0.195 | – | – | |||
| increase) | ||||||||
| Comorbid disease (presence compared | 1.187 | 0.741– 1.889 | 0.476 | – | – | NS | ||
| to absence) | ||||||||
| Started treatment choice | ||||||||
| cNRT | 1 | 1 | ||||||
| Bupropion | 3.908 | 1.566–9.753 | 0.003 | 5.185 | 1.929–13.935 | 0.001 | ||
| Varenicline | 6.610 | 2.599–16.810 | 0.001 | 8.987 | 3.258–24.787 | 0.001 | ||
| Started treatment choice | ||||||||
| Bupropion | 1 | |||||||
| cNRT | 0.25 | 0.103–0.639 | 0.003 | Not adjusted in multivariate analysis | ||||
| Varenicline | 1.69 | 1.065–2.685 | 0.026 | |||||
| Adverse reaction (absence compared to presence) | 2.091 | 1.238–3.532 | 0.006 | 3.326 | 1.868–5.924 | 0.001 | ||
| Control visit number (per 1 visit increase) | 1.599 | 1.283–1.993 | 0.001 | 1.708 | 1.353–2.156 | 0.001 | ||
Backward Stepwise (likelihood ratio): -2 LOG likelihood: 406.928. Nagelkerke R Square: 0.220. Omnibus tests of model coefficient: p=0.000. Durbin-Watson test: 1.96